Characteristics | Without adjustment for other covariates | With adjustment for other covariates | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. of trials, m | Fitted mean | 95% CI | F test | p value | No. of trials, m | Fitted mean | 95% CI | F test | p value | ||
Prevalence class | 17.38 | <.0001 | 20.73 | <.0001 | |||||||
<1/1,000,000 | 19 | 21.21 | (11.63–38.67) | 18 | 28.61 | (14.43–56.73) | |||||
1–9/1,000,000 | 88 | 40.57 | (32.18–51.14) | 66 | 55.23 | (33.76–90.37) | |||||
1–9/100,000 | 587 | 74.19 | (67.71–81.29) | 483 | 90.09 | (58.66–138.36) | |||||
1–5/10,000 | 454 | 86.37 | (78.32–95.25) | 359 | 93.10 | (60.58–143.08) | |||||
Phase of investigation b | 21.56 | <.0001 | 324.97 | <.0001 | |||||||
Phase 2 | 841 | 32.84 | (28.61–37.69) | 677 | 46.34 | (29.86–71.90) | |||||
Phase 3 | 307 | 71.50 | (53.05–96.38) | 249 | 78.57 | (47.48–130.02) | |||||
Prevalence × Phase | 6.40 | 0.0003 | 2.75 | 0.0415 | |||||||
Phase 2 | <1/1,000,000 | 16 | 18.05 | (11.20–29.09) | 15 | 26.96 | (14.74–49.31) | ||||
1–9/1,000,000 | 65 | 35.23 | (27.80–44.65) | 48 | 49.04 | (29.87–80.51) | |||||
1–9/100,000 | 442 | 41.52 | (37.92–45.47) | 365 | 58.70 | (38.14–90.32) | |||||
1–5/10,000 | 318 | 44.04 | (39.57–49.02) | 249 | 59.42 | (38.62–91.43) | |||||
Phase 3 | <1/1,000,000 | 3 | 24.92 | (8.28–75.06) | 3 | 30.37 | (10.37–88.92) | ||||
1–9/1,000,000 | 23 | 46.71 | (31.37–69.56) | 18 | 62.21 | (34.40–112.49) | |||||
1–9/100,000 | 145 | 132.56 | (113.12–155.35) | 118 | 138.28 | (88.39–216.34) | |||||
1–5/10,000 | 136 | 169.39 | (143.80–199.53) | 110 | 145.86 | (92.79–229.30) |